Connor Clark & Lunn Investment Management Ltd. Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Connor Clark & Lunn Investment Management Ltd. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 95.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 934 shares of the biopharmaceutical company's stock after selling 19,577 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.'s holdings in Regeneron Pharmaceuticals were worth $665,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Thrivent Financial for Lutherans increased its stake in Regeneron Pharmaceuticals by 16.7% during the third quarter. Thrivent Financial for Lutherans now owns 9,120 shares of the biopharmaceutical company's stock worth $9,587,000 after acquiring an additional 1,306 shares during the last quarter. Prospera Financial Services Inc purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $778,000. PNC Financial Services Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 18,325 shares of the biopharmaceutical company's stock valued at $19,264,000 after purchasing an additional 153 shares during the last quarter. Integrated Investment Consultants LLC raised its holdings in Regeneron Pharmaceuticals by 85.1% during the 3rd quarter. Integrated Investment Consultants LLC now owns 570 shares of the biopharmaceutical company's stock valued at $599,000 after buying an additional 262 shares during the period. Finally, Pacer Advisors Inc. raised its stake in shares of Regeneron Pharmaceuticals by 18.7% in the third quarter. Pacer Advisors Inc. now owns 19,540 shares of the biopharmaceutical company's stock valued at $20,541,000 after acquiring an additional 3,076 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of analysts have weighed in on REGN shares. Bank of America reiterated an "underperform" rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Canaccord Genuity Group began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Citigroup decreased their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Finally, Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $6.00 during mid-day trading on Wednesday, hitting $640.14. 1,251,794 shares of the stock were exchanged, compared to its average volume of 639,898. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $630.62 and a 52-week high of $1,211.20. The firm has a fifty day moving average of $687.18 and a 200 day moving average of $806.20. The company has a market cap of $69.98 billion, a PE ratio of 16.72, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $11.86 earnings per share. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.